Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lifespot Health (LSH) has granted fellow ASX lister, Jayex Healthcare (JHL), a software licence agreement for its BodyTel software platform and Bluetooth technology
  • The initial five year licence deal is exclusive in the U.K. and non-exclusive in Australia and New Zealand
  • Lifespot’s technologies include medical diagnostic and monitoring technology that allows patients, their family and caregivers to monitor conditions through mobile devices
  • Jayex’s Connect platform will also be integrated into the offering
  • The companies believe this deal is timely as there is a greater importance on providing remote monitoring capabilities to GPs post-COVID-19
  • Lifespot’s shares remain in the grey and are trading for 3.5 cents each while Jayex’s shares are also trading in the grey for 2.5 cents each

Lifespot Health (LSH) has executed a software licence agreement with Jayex Healthcare (JHL) to license its BodyTel software platform.

The agreement also includes the sale of Lifespot’s integrated Bluetooth technology products and services to Jayex.

Lifespot granted Jayex an exclusive licence for the United Kingdom and a non-exclusive licence for Australia and New Zealand, to market and sell BodyTel, Bluetooth products as well as future telehealth products developed during the agreement term.

BodyTel will be integrated into Jayex’s Connect platform to enhance the capacity of over 20,000 GPs in its U.K.-based Connect ecosystem.

“By adding this capability to our market-leading Jayex Connect platform we will have one of the most comprehensive patient management systems available to GPs and respond to the increasing demand for telehealth and remote patient management options,” Jayex CEO Nick Fernando said.

The licence agreement is for an initial five year term, with one additional five year extension option.

Jayex will pay Lifespot a licence fee based on the revenue it generates from the technology, as well as maintenance service fees and development fees.

Lifespot’s BodyTel software platform and Bluetooth technologies include medical diagnostic and monitoring technology as well as digitally-enabled drug delivery systems to combine sensor technology with self-learning algorithms.

It allows patients, their loved ones, and caregivers to monitor chronic diseases and critical conditions just by using their smartphones.

Lifespot and Jayex believe this licence agreement is timely as there is a greater importance placed on providing GP clinics with remote monitoring capabilities post-COVID-19.

Lifespot’s shares remain in the grey and are trading for 3.5 cents each and Jayex’s shares are also trading in the grey for 2.5 cents each at market close.

LSH by the numbers
More From The Market Herald
Bill Identity (ASX:BID) - Incoming CEO, Michele Garra (left)

" Bill Identity (ASX:BID) appoints Michele Garra as new CEO

Bill Identity (BID) has appointed a Telstra and Optus senior executive as its new Chief Executive Officer.
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Peppermint Innovation (ASX:PIL) - CEO and Managing Director, Chris Kain

" Peppermint Innovation (ASX:PIL) signs with payment gateway Dragonpay

Peppermint Innovation (PIL) has signed an agreement with one of the Philippines’ largest and most reliable online payment gateway platforms, Dragonpay.